Welcome to our dedicated page for Shoulder Innovations news (Ticker: SI), a resource for investors and traders seeking the latest updates and insights on Shoulder Innovations stock.
Shoulder Innovations develops and commercializes medical technology for the shoulder surgical care market, with implant systems for total and reverse shoulder arthroplasty and related tools for preoperative planning and procedural efficiency. Its ecosystem includes InSet shoulder arthroplasty systems, the ProVoyance planning platform, instrument systems, specialized support and surgeon collaboration.
Company news commonly covers product launches and FDA 510(k) clearances, including additions to the I-Series portfolio, quarterly and annual financial results, enabling-technology partnerships, board and committee changes, and management presentations at medical technology and musculoskeletal conferences.
Shoulder Innovations (SI) received FDA 510(k) clearance for its N-22 Humeral Head titanium implant for metal-hypersensitive shoulder patients and initiated full commercial launch in the United States.
The device is intended for use in anatomic total shoulder arthroplasty in patients who have complications related to metal hypersensitivity, a condition affecting an estimated 10% to 15% of the general population. The N-22 Humeral Head complements the company’s N-22 Glenosphere implant, which was cleared in January 2026 for reverse total shoulder arthroplasty in the same patient group. Management said this addition gives surgeons a metal-sensitive option across both major shoulder arthroplasty configurations and may strengthen relationships with surgeons and operating centers as the company expands its U.S. commercial footprint.
Shoulder Innovations (NYSE: SI) has entered an exclusive collaboration with ALM Ortho to introduce a bespoke implant solution for severe shoulder deformities and complex revision procedures in the United States.
The implant is designed case by case using patient imaging data, creating personalized titanium orthopedic devices tailored to individual anatomy. Shoulder Innovations holds exclusive rights for upper extremity applications of ALM Ortho’s solutions in the U.S.
Shoulder Innovations will use its surgeon relationships and sales organization to identify suitable cases and connect surgeons and facilities to the ALM Ortho solution, while ALM Ortho will design, manufacture, and deliver the custom implants. Specific financial terms of the agreement are confidential.
Shoulder Innovations (SI) has entered into a settlement agreement with Catalyst OrthoScience to resolve all outstanding patent litigation between the companies.
The settlement terms are confidential. CEO Rob Ball said the resolution provides an agreeable solution to the patent dispute and emphasized that protecting intellectual property is fundamental to supporting the company’s investments in innovation. The company believes the outcome allows it to continue focusing on advancing shoulder arthroplasty and delivering improved outcomes for surgeons and patients.
Shoulder Innovations (NYSE: SI) announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Healthcare Conference on Tuesday, September 15, 2026, at 3:20 p.m. ET / 12:20 p.m. PT. A live and archived webcast will be accessible via the company’s Investor Relations website.
Shoulder Innovations (NYSE: SI) announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026. He previously served as Vice President of Commercial Development and will now oversee all elements of the company’s commercial organization.
According to Shoulder Innovations, Osborne will work closely with the Customer Experience and Medical Education team to execute the company’s commercial strategy and support scaling adoption of its shoulder-focused product portfolio. He brings prior leadership experience from Smith & Nephew, ArthroCare, Tornier USA, and Team Surgical, with responsibilities across sales, global marketing, and commercial growth.
Shoulder Innovations (NYSE: SI) reported second quarter 2026 net revenue of $17.2 million, up 56% from $11.0 million a year earlier, driven by higher implant volumes and more customers. Gross margin rose to 78.3% from 76.2%, with average implant system selling price increasing 5% to $7,674.
The company sold 2,238 implant systems in Q2, approximately 50% more than in Q2 2025. Selling, general and administrative expenses grew 56% to $20.1 million, and R&D expenses rose 141% to $3.4 million, leading to an operating loss of $10.0 million.
Net loss was $10.2 million, while Adjusted EBITDA loss improved to $8.0 million from $18.1 million, largely due to the absence of prior-year fair value charges. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $99.0 million. The company closed two new credit facilities totaling up to $50 million and raised full-year 2026 net revenue guidance to $67–$69 million, implying 42–46% growth over 2025.
Shoulder Innovations (NYSE: SI), a commercial-stage medical technology company focused on shoulder surgical care, announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference. The presentation is scheduled for 1:30 p.m. ET / 10:30 a.m. PT on Wednesday, August 12, 2026, with a live and archived webcast available in the Investor Relations section of the company’s website.
Shoulder Innovations (NYSE: SI), a commercial-stage medical technology company focused on shoulder surgical care, will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT, accessible by phone and via live and archived webcast in the Investor Relations section of the company’s website.
Shoulder Innovations (NYSE: SI) closed new credit facilities totaling up to $50 million with Stifel Venture Banking, refinancing its existing debt.
The package includes a fully funded $15 million term loan, a $30 million undrawn line of credit, and a $5 million accordion, with no added indebtedness at closing and no warrants.
Shoulder Innovations (NYSE:SI), a commercial-stage medical technology company focused on shoulder surgical care, announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 9, 2026.